Analysts Set Expectations for AngioDynamics Q1 Earnings

Key Points

• HC Wainwright analysts forecast AngioDynamics will report Q1 2027 earnings per share of ($0.09), maintaining a "Buy" rating with a target price of $16.00.
• In its latest earnings report, AngioDynamics exceeded expectations by posting ($0.10) EPS and generated revenues of $75.71 million, indicating a year-over-year revenue increase of 12.1%.
• Recent analysis shows a mix of ratings for AngioDynamics, with three analysts recommending a “Buy” and one a “Sell”, while the average target price is $19.33.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of AngioDynamics in a note issued to investors on Monday, October 6th. HC Wainwright analyst Y. Chen anticipates that the medical instruments supplier will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics' Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.02 EPS and FY2027 earnings at ($0.18) EPS.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $75.71 million during the quarter, compared to the consensus estimate of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The firm's revenue for the quarter was up 12.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS.

Several other equities research analysts also recently commented on the company. Lake Street Capital initiated coverage on AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a report on Saturday, September 27th. Canaccord Genuity Group raised their price target on AngioDynamics from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday. Finally, Wall Street Zen downgraded AngioDynamics from a "buy" rating to a "hold" rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $19.33.

AngioDynamics Trading Down 1.9%

NASDAQ ANGO opened at $11.05 on Wednesday. The company has a market cap of $455.26 million, a PE ratio of -14.17 and a beta of 0.78. AngioDynamics has a 12 month low of $5.84 and a 12 month high of $13.50. The stock has a 50 day moving average of $10.02 and a 200-day moving average of $9.78.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in AngioDynamics by 13.5% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier's stock valued at $166,000 after buying an additional 1,989 shares during the period. Cerity Partners LLC lifted its stake in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 2,333 shares during the period. Rhumbline Advisers lifted its stake in AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier's stock valued at $608,000 after buying an additional 2,510 shares during the period. Invesco Ltd. lifted its stake in AngioDynamics by 2.2% in the second quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier's stock valued at $1,216,000 after buying an additional 2,667 shares during the period. Finally, State of Wyoming acquired a new position in AngioDynamics in the second quarter valued at approximately $31,000. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.